New Orleans—Researchers have demonstrated that a new primary prevention strategy may reduce cardiovascular events in certain patients at risk of cardiovascular disease.
At the Scientific Sessions of the American Heart Association (AHA) held here in November, scientists reported that among apparently healthy patients with elevated levels of high-sensitivity C-reactive protein (hsCRP, an inflammatory biomarker) but without elevated low-density lipoprotein cholesterol (LDL-C) levels (< 130 mg/dL), using a statin reduced the LDL-C levels and significantly reduced the risk of myocardial infarction, stroke, and death.
Mitka M. Studies Examine Inflammatory Biomarker in Prevention and Prediction of Heart Disease. JAMA. 2009;301(1):23-24. doi:10.1001/jama.2008.876